Jpmorgan Chase & CO Vista Gen Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 18, 2023	BUY	$0.12 - $0.3 $19,023 - $47,559	158,531 Added 33165.48%	159,009 $19,000
Q1 2023 May 11, 2023	SELL	$0.12 - $0.3 $13,227 - $33,069	-110,231 Reduced 99.57%	478 $0
Q4 2022 Feb 13, 2023	BUY	$0.09 - $4.8 $172 - $9,182	1,913 Added 1.76%	110,709 $11,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $4.8 $635 - $21,782	4,538 Added 4.35%	108,796 $17,000
Q2 2022 Aug 11, 2022	BUY	$0.88 - $1.73 $11,544 - $22,695	13,119 Added 14.39%	104,258 $92,000
Q1 2022 May 11, 2022	BUY	$1.14 - $2.09 $18,283 - $33,519	16,038 Added 21.36%	91,139 $113,000
Q4 2021 Feb 10, 2022	SELL	$1.67 - $2.76 $200,790 - $331,845	-120,234 Reduced 61.55%	75,101 $147,000
Q3 2021 Nov 12, 2021	BUY	$2.62 - $3.45 $511,777 - $673,905	195,335 New	195,335 $536,000

27.1K

Ticker VTGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 206,836,000
Market Cap $517M
Description
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.